Contemporary Approaches to Modulating the Nitric Oxide–cGMP Pathway in Cardiovascular Disease

Contemporary Approaches to Modulating the Nitric Oxide–cGMP Pathway in Cardiovascular Disease

Jan R. Kraehling, William C. Sessa

Proteins and enzymes involved in the nitric oxide (NO)-nitric oxide–sensitive guanylate cyclase (NOsGC)–cGMP pathway and its modulators. Key players of the pathway are shown in blue, the positive modulators are shown in yellow, and the negative modulators in purple. Endothelial cells (EC) are shown in green (top), whereas the vascular smooth muscle cell (VSMC) is shown in red (bottom). The space between the 2 cells is called myoendothelial junction (MEJ). cGMP mediates its cellular functions through cGMP-modulated (cyclic nucleotide-gated [CNG]) cation channels, cGMP-dependent protein kinases (cGKs) and cGMP-regulated phosphodiesterases (PDEs). BH4 indicates tetrahydrobiopterin; CAV1, caveolin-1; CYB5R3, NADH-cytochrome b5 reductase 3; eNOS, endothelial nitric oxide synthase (NOS3); Hb2+/Hb3+, hemoglobin α (reduced/oxidized); and PDE, phosphodiesterase. [Powerpoint File]

Comments are Disabled